Clinical trials: Ticagrelor
Acute Coronary Syndrome
Ticagrelor Monotherapy Compared to Aspirin Monotherapy in Patients With History of ACS
Antiplatelet agents are cornerstones for management of ischemic heart disease. For patients suffering from acute coronary syndrome (heart attack), treatment with aspirin and ticagrelor are typically given for one year after index…
- Trial name
- FMD_ACS (NCT03881943)
- Testing
- Ticagrelor 60 mg, Aspirin 100 MG Oral Tablet, Enteric Coated
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The University of Hong Kong
Coronary Artery Disease (CAD)
Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics Profile
Several studies have shown that pharmacodynamic (PD) response varies between patients treated with clopidogrel and that individuals with reduced response have an increased risk of recurrent ischemic events, particularly in…
- Trial name
- NCT05516784
- Testing
- Clopidogrel, Ticagrelor
- Where
- Malaysia
- Volunteers
- 80 people
- Sponsor
- Universiti Sains Malaysia
Hemorrhage, Urgent Surgery
Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure
This is a multi-center, open-label, prospective single-arm study of reversal of the antiplatelet effects of ticagrelor with bentracimab (PB2452) in patients who present with uncontrolled major or life-threatening bleeding or who…
- Conditions
- Hemorrhage, Urgent Surgery, Invasive Procedure
- Trial name
- REVERSE-IT (NCT04286438)
- Testing
- Bentracimab (PB2452) Infusion
- Where
- 68 sites in United States, Austria and 11 more
- Volunteers
- 226 people
- Sponsor
- SFJ Pharmaceuticals, Inc.
Coronary Artery Disease
Prasugrel 5 mg vs. Ticagrelor 60 mg in CHIP (E5TION)
E5TION will evaluate the efficacy, safety and tolerability of tailored two regimens (prasugrel 5mg/d vs. ticagrelor 60mg bid) in high-risk patients undergoing PCI (CHIP: COmplex and Higher-Risk Indicated PCI/PatieNts).
- Trial name
- E-5TION (NCT04734353)
- Testing
- Prasugrel 5mg, Ticagrelor 60mg
- Where
- 8 sites in South Korea
- Volunteers
- 492 people
- Sponsor
- Gyeongsang National University Hospital
Coronary Artery Bypass, Antiplatelet Agents
Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery
The study population will include all patients undergoing elective CABG. Consent and randomization will occur before surgery. Total 500 patients undergoing elective CABG will be randomly assigned into three groups with 1:1:1…
- Trial name
- DACAB (NCT02201771)
- Testing
- Aspirin, Ticagrelor
- Where
- 6 sites in China
- Volunteers
- 500 people
- Sponsor
- Ruijin Hospital
Acute Coronary Syndromes, ST Elevation Myocardial Infarction
Chewing Versus Traditional Oral Administration of Ticagrelor in STEMI Patients
To examine chewing versus traditional oral administration of ticagrelor in ST-elevation Myocardial Infarction (STEMI) patients on platelet reactivity.
- Trial name
- NCT02725099
- Testing
- Chewing Ticagrelor, Oral Ticagrelor
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Sheba Medical Center
Blood Flow Speed, Coronary Flow Velocity
Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects.
The purpose of this study is to determine if Ticagrelor increases the Adenosin induced coronary blood flow velocity.
- Trial name
- NCT01226602
- Testing
- AZD6140
- Where
- Sweden
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Dual Antiplatelet Therapy, Platelet Reactivity
Is There a Transient Rebound Effect of Platelet Reactivity Following Cessation of Dual Antiplatelet Therapy With Ticagrelor - a Single Center Prospective Observational Trial
to assess whether cessation of 12 months DAPT regimen containing Ticagrelor results in a hyperreactive phase of platelet function
- Trial name
- NCT02808039
- Testing
- Platelet reactivity testing
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Rabin Medical Center
Thrombosis
To Evaluate the Safety and Tolerability of Combined Administration of SHR2285 Tablets With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects
The study is a single-center，randomized, doubled-blinded, placebo-controlled, Only for SHR2285 Phase I trial. This study intends to enroll 52 healthy subjects, regardless of gender.
- Trial name
- NCT04945616
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Fractional Flow Reserve
Effect of Ticagrelor on Fractional Flow Reserve
Fractional flow reserve (FFR) is an established invasive method for assessing the physiological significance of coronary artery stenosis.
- Trial name
- NCT02108808
- Testing
- Ticagrelor, Prasugrel or Clopidogrel
- Where
- Greece
- Volunteers
- 76 people
- Sponsor
- University of Patras
Blood Loss, Surgical, Ticagrelor
Comparison of CABG Related Bleeding Complications in Patients Treated With Ticagrelor or Clopidogrel
In patients with coronary artery disease, dual antiplatelet therapy (acetylsalicylic acid and a P2Y12-receptor antagonist) is a commonly used method because of its excellent antithrombotic effect.
- Conditions
- Blood Loss, Surgical, Ticagrelor, Clopidogrel
- Trial name
- CABG (NCT04431349)
- Testing
- Ticagrelor 180mg, Clopidogrel 75mg
- Where
- South Korea
- Volunteers
- 1,097 people
- Sponsor
- Ajou University School of Medicine
Acute Coronary Syndrome
Platelet Reactivity Inhibition Following Ticagrelor Loading Dose and One Year Outcome
This study will try to determine if the measure of the platelet reactivity of the patients receiving from the ticagrelor continuation in an acute coronary syndrome handled by coronary angioplasty allows to predict the hemorrhagic…
- Trial name
- NCT02428725
- Testing
- blood sample
- Where
- France
- Volunteers
- 640 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Coronary Artery Disease
Ticagrelor vs Clopidogrel Effect on MFR in CAD Population
Ticagrelor is one of 3 anti-platelet medications used in patients with acute coronary syndrome (ACS) to prevent further clot formation and further ischemic damage to myocardial tissue.
- Trial name
- PATH (NCT01894789)
- Testing
- Ticagrelor, Clopidogrel
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Coronary Artery Disease
The Platelet Aggregation After tiCagrelor Inhibition and FentanYl Trial (PACIFY)
With potent analgesic properties, perceived hemodynamic benefits and limited alternatives, opiates are the analgesic mainstay for acute coronary syndrome (ACS) patients reporting peri-procedural pain or nitrate-resistant chest…
- Trial name
- PACIFY (NCT02683707)
- Testing
- Removal of Fentanyl from peri-procedural analgesia, Fentanyl, Lidocaine
- Where
- United States
- Volunteers
- 212 people
- Sponsor
- Johns Hopkins University
Antiplatelet Agents; Endothelial Function; Pleotropic Effects
Ticagrelor and Endothelial Function
To evaluate the effect of ticagrelor on endothelial function as measured by flow mediated dilation of the brachial artery. This will be compared to prasugrel.
- Trial name
- NCT02261922
- Testing
- ticagrelor, prasugrel
- Where
- Lebanon
- Volunteers
- 20 people
- Sponsor
- Hotel Dieu de France Hospital
ST-elevation Myocardial Infarction
Standard (180mg) Versus Double (360mg) Loading Dose of Ticagrelor in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
This is a multi-center, prospective, randomized, single-blind, investigator initiated, pharmacodynamic study of parallel design, performed at 3 institutions (Patras University Hospital; Evangelismos Athens General Hospital…
- Trial name
- NCT01575795
- Testing
- Ticagrelor
- Where
- Greece
- Volunteers
- 83 people
- Sponsor
- University of Patras
PRU, miRNA
The Relationship of Platelet Micro-RNA Expression and Platelet Reactivity in Patients Under Clopidogrel or Ticagrelor Treatment
For acute coronary syndrome patients undergoing cardiac catheterization after stenting, we will give dual antiplatelet drugs (dual antiplatelet agents) therapy, the choice of the basis of medical criteria (clinical guidelines)…
- Trial name
- NCT02101437
- Testing
- miRNA within 24hr, miRNA after 1 week, miRNA after 1 month
- Where
- Taiwan
- Volunteers
- 175 people
- Sponsor
- Taipei City Hospital
Acute ST Segment Elevation Myocardial Infarction, Thrombolysis in Myocardial Infarction Flow
Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis
Administration of Ticagrelor in patients with ST elevation myocardial infarction treated with pharmacological thrombolysis
- Trial name
- TREAT (NCT02298088)
- Testing
- Ticagrelor 180 mg, Clopidogrel
- Where
- 153 sites in Argentina, Australia and 8 more
- Volunteers
- 3,799 people
- Sponsor
- Hospital do Coracao
Acute Coronary Syndrome
ARCANGELO (itAlian pRospective Study on CANGrELOr)
The Sponsor implemented a post-authorisation safety study (PASS), category 3, focused in Acute Coronary Syndrome, in order to collect information about the safety of cangrelor in the real clinical practice, evaluating the safety…
- Trial name
- ARCANGELO (NCT04471870)
- Where
- 30 sites in Italy
- Volunteers
- 1,005 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Acute Coronary Syndrome, Non ST Elevation Myocardial Infarction
Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor .
Study design Investigators aim to perform a prospective, single-center, investigator-initiated, randomized study to compare the Adenosine-induced coronary vasodilatation after the loading dose of Ticagrelor either Prasugrel…
- Conditions
- Acute Coronary Syndrome, Non ST Elevation Myocardial Infarction, ST Elevation Myocardial Infarction, Unstable Angina
- Trial name
- NCT02032303
- Testing
- Assessment of coronary flow reserve, Percutaneous Coronary Intervention, Ticagrelor loading
- Where
- Italy
- Volunteers
- 88 people
- Sponsor
- Azienda Policlinico Umberto I